期刊文献+

老年单纯收缩期高血压患者左心功能变化的可能机制 被引量:2

Possible mechanism on changes of left-ventricular function in elderly isolated systolic hypertension
原文传递
导出
摘要 目的探讨血CD34+、Toll样受体2(TLR2)、Toll样受体4(TLR4)和高敏c反应蛋白(hs—CRP)的水平变化与老年人单纯收缩期高血压(EISH)患者左心功能的关系。方法2008年2月至2010年2月徐州医学院淮安附属医院老年病科入住EISH合并慢性左心衰竭患者98例和同期健康体检者30例(对照组)。根据美国纽约心脏病学会(NYHA)心功能分级、左心室射血分数(LVEF)和收缩压将EISH患者分I级组25例、Ⅱ级组29例、Ⅲ级组24例和Ⅳ级组20例。使用双标记单克隆抗体和相应的对照抗体(由美国Beckman Coulter公司提供)标记血液中的白细胞,测定外周血CD34+,采用流式细胞仪检测对照组和EISH患者TLR2和TLR4的平均荧光强度(MFI),免疫散射比浊法测定hs—CRP的水平。结果I级组、Ⅱ级组、Ⅲ级组、Ⅳ级组LVEF分别为(40.5±3.6)%、(30.8±2.5)%、(28.5±1.9)%和(26.4±2.1)%,收缩压分别为(151.1±5.9)mmHg(1mmHg=0.133kPa)、(171.1±6.0)mmHg、(190.7±7.3)mmHg和(211.1±8.4)mmHg。IV级组和I级组比较,LVEF、收缩压、CD34+[分别为(0.5±0.2)×10^9/L和(2.5±0.4)×10^9/L]、TLR2[(8.0±1.0)MFI与(3.2±1.1)MFI]、TLR4[(6.4±1.3)MFI与(2.4±1.1)MFI]、hs—CRP[(14.7±0.3)mg/L与(4.90±0.61)mg/L]差异有统计学意义(均P〈0.05)。结论TLR2、TLR4和hs—CRP水平增高及CD34+水平的下降与收缩压升高、LVEF下降和NYHA心功能分级升高相关。 Objective To study the relationship of left-ventricular function change with circulation levels of CD34+ cells, toll like receptor 2 (TLR2) , TLR4 and high-sensitivity C-reactive protein (hs-CRP)in elderly isolated systolic hypertension. Methods According to New York Heart Association (NYHA)class, left ventricular ejection fraction (LVEF) and systolic blood pressure (SBP) ,the healthy subjects and the patients were divided into 5 groups: control 30 cases, class I 25 cases, class II 29 cases, class III 24 cases and class IV 20 cases. The expressions of circulating CD34 + cells, TLR2 and TLR4 in the patients and healthy subjects were measured by flow cytometry. The level of hs-CRP was measured by nephelometry immunoassay. Results In class IV versus class I , the levels of LVEF[(26.4±2.1)%vs. (40.5±3.6)%] and CD34+ [(0.5±0.2)×10^9 vs. (2.5± 0. 4) ×10^9/L] were decreased, whileSBP[(211.1±8.4)mm Hg vs. (151.1±5.9)mm Hg], TLR2 [(8.0±1.0) vs. (3.2±1. 1)MFI], TLR4 [(6.4±1. 3)MFT vs. (2.4±1. 1)MFI] and hs-CRP [(14.7±0.3)mg/L vs. (4.9±0.6)mg/L] were increased (all P〈0.05). Conclusions The lower levels of CD34+ cells, higher TLR2, TLR4 and hs-CRP levels are correlated with increasing SBP, decreasing LVEF and higher NYHA class.
出处 《中华老年医学杂志》 CAS CSCD 北大核心 2012年第9期753-757,共5页 Chinese Journal of Geriatrics
基金 基金项目:江苏省高校自然科学研究计划项目(KJD310234) 江苏省淮安市科技局科技项目(HAS04020) 江苏省淮安市科技支撑计划项目(HAS2011020)
关键词 高血压 心室功能 C反应蛋白 TOLL样受体2 抗原 CD34 Hypertension Ventricular function, left C-reactive protein Toll-like receptor 2 Antigens, CD34
  • 相关文献

参考文献21

  • 1Logan AG. Hypertension in aging patients. Expert Rev Cardiovasc Ther, 2011, 9:113-120.
  • 2华琦.老年单纯收缩期高血压的发病特点和治疗对策[J].中国心血管杂志,2010,15(4):257-259. 被引量:7
  • 3Ahmed A. DEFEAT heart failure : clinical manifestations, diagnostic assessment, and etiology of geriatric heart failure. Heart Failure Clin, 2007, 3 : 389-402.
  • 4Vidan MT, Bueno H, Wang Y, et al. The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. EurJ Heart Fail, 2010, 2:148-155.
  • 5GimelIi A, Landi P, Marraccini P, et al. Left ventricular ejection fraction measurements: accuracy and prognostic implications in a large population of patients with known or suspected ischemic heart disease. Int J Cardiovasc Imaging, 2008, 24: 793- 801.
  • 6Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/ AHA 2011 expert consensus document on hypertension in the elderly: a report of the american college of cardiology foundation task force on clinical expert consensus documents. Circulation, 2011, 123 :2434-2506.
  • 7Oliveras A,Soler MJ, Martinez-Estrada OM, et al. Endothelial progenitor cells are reduced in refractory hypertension. J HumHypertens, 2008, 22:183-190.
  • 8Eunju O, I.ee BH, Ahn HY, et al. Efficient nonadhesive exvivo expansion of early endothelial progenitor cells derived from CD34 + human cord blood fraction for effective therapeutic vascularization. FASEB J, 2011, 25 : 159-169.
  • 9Giannotti G, Doerries C, Moeharla PS, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension, 2010, 55:1389-1397.
  • 10Eissler R, Schmaderer C, Rusai K, et al. Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res, 2011, 34: 551-558.

二级参考文献16

  • 1Hansson L.The Hypertension Optimal Treatment study (the HOT Study).Blood Press,1993,2:62-68.
  • 2Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial.Lancet,1998,351:1755-1762.
  • 3Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens,2007,25:1105-1187.
  • 4Herzog CA.Can we prevent sudden cardiac death in dialysis patients? Clin J Am Soc Nephrol,2007,2:410-412.
  • 5Skorecki KL,Winaver J,Abassi ZA.Extracellular fluid and edema formation.In:Brenner and Rector's The Kidney,8th ed,edited by Brenner BM.Philadelphia:Saunders Elsevier,2008:398-458.
  • 6Dao Q,Krishnaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.J Am Coll Cardiol,2001,37:379-385.
  • 7Chan D,Ng LL.Biomarkers in acute myocardial infarction.BMC Medicine,2010,8:34.
  • 8Madsen LH,Ladefoged S,Correll P,et al.N-terminal pro-brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.Kidney Int,2007,71:548-554.
  • 9Foley RN,Curtis BM,Randell EW,et al.Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.Clin J Am Soc Nephrol,2010,5:805-813.
  • 10Kasner M,Westerm ann D,Steendijk P,et al.Utility of doppler echocardiography and Tissue doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction:a comparative Doppler conductance catheterization study.Circulation,2007,116:637-647.

共引文献18

同被引文献25

  • 1刘英春,白丽.原发性高血压患者服用硝苯地平控释片后血管内皮功能的改变[J].世界临床药物,2007,28(1):10-13. 被引量:4
  • 2徐红,王洁.复方丹参滴丸对急性心肌梗死后患者存活率的影响[C].复方丹参滴丸美国FDA II期临床试验结果报告暨第四届学术研讨会论文集,2010:258-259.
  • 3Atanasijevi-Kunc,M.,Drinovec,J.,Ruigaj,S.et al.Simulation analysis of coronary heart disease,congestive heart failure and end-stage renal disease economic burden[J].Mathematics and computers in simulation,2011,82(3):494-507.
  • 4王伺伟,颜怀银,陈绍曾,等.盐酸乌拉地尔与硝酸甘油治疗高血压合并急性左心衰竭疗效比较[C].中国医师协会急诊医师分会第一届全国年会论文集,2010:401-402.
  • 5ho,T.-J.,Huang,C.-C.,Huang,C.-Y.et al.Nifedipine controlled release tablets,a Rho-kinase inhibitor,protects against excessive endurance exercise training-induced cardiac hypertrophy,apoptosis and fibrosis in rats[J].European journal of applied physiology,2012,112(8):2943-2955.
  • 6Leask A.Potential therapeutic targets for cardiac fibrosis:TGFbeta,angiotensin,endothelin,CCN2,and PDGF,partners in fibroblast activation.Circ Res,2010,106:1675-1680.
  • 7Anversa P,Olivetti G,Melissari M,et al.Morphometric study of myocardial hypertrophy induced by abdominal aortic stenosis.Lab Invest,1979,40:341-349.
  • 8Ho CY,Lopez B,Coelho-Filho OR,et al.Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.N Engl J Med,2010,363:552-563.
  • 9Daniels A,van Bilsen M,Goldschmeding R,etal.Connective tissuc growth factor and cardiac fibrosis.Acta Physiol (Oxf),2009,195:321-338.
  • 10wamoto M,Hirohata S,Ogawa H,et al.Connective tissue growth factor induction in a pressure-overloaded heart ameliorated by the angiotensin Ⅱ type 1 receptor blocker olmesartan.Hypertens Res,2010,33:1305-1311.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部